SAN FRANCISCO: Gilead Sciences Inc shares fell as first-quarter sales of its antiviral treatments for hepatitis C and HIV failed to meet analysts’ expectations.
Truvada, a treatment for HIV, was the biggest disappointment, while Epclusa and Sovaldi for viral liver disease also fell short of analysts’ projections. Gilead fell 2.4% to $66.92 at 6.37pm in New York after US markets closed.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
